Table 3.
Number of clinical events observed in each group.
| Variables | GS-3K8 group (n = 14) | GINST group (n = 15) | Placebo group (n = 15) |
|---|---|---|---|
| Primary clinical outcome, n (%; 95% CI) | |||
| ARI | 9 (64.3; 31.4–91.1) | 4 (26.7; 4.3–49.0) | 12 (80.0; 54.8–93.0) |
| Secondary clinical outcomes, n, mean days ± SD | |||
| Symptoms and duration | |||
| Sore throat | 0 | 1, 2 | 5, 3.80 ± 2.49 |
| Coryza | 7, 2.57 ± 1.13 | 3, 5.00 ± 3.00 | 8, 6.50 ± 3.25 |
| Nasal congestion | 0 | 0 | 6, 4.00 ± 2.76 |
| Sneezing | 6, 2.33 ± 1.03 | 0 | 3, 7.67 ± 7.23 |
| Hoarseness | 2, 1.00 ± 0.00 | 1, 5 | 5, 10.00 ± 9.25 |
| Myalgia | 1, 1 | 0 | 2, 2.00 ± 0.00 |
| Otalgia | 0 | 0 | 0 |
| Fever | 0 | 1, 1 | 1, 1 |
| Headache | 1, 1 | 1, 1 | 4, 6.00 ± 6.06 |
| Cough | 3, 7.00 ± 6.93 | 3, 9.33 ± 9.45 | 7, 10.43 ± 12.63 |
| Total | 9, 3.89 ± 4.65 | 4, 9.25 ± 1.22 | 12, 12.25 ± 12.69 |
ARI, acute respiratory illness; CI, confidence interval; SD, standard deviation.